Détail de l'auteur
Auteur Tremblay J |
Documents disponibles écrits par cet auteur (15)
trié(s) par (Date de parution décroissant(e), Date de parution décroissant(e), Système de projection du document croissant(e)) | Mettre toutes les notices dans le panier | Faire une suggestion | Ajouter un critère de recherche
Article
Lapointe E ; Fujii I ; Makoto M ; Tremblay J | 2008Human embryonic stem cells (hESC) have a self-renewal capacity and can differentiate into all cells find in the body. For this reason, they represent an unlimited source of cells for the treatment of degenerative disease, such as Duchenne Muscul[...]Article
Congrès international de myologie 2008 (International Congress of Myology 2008; 26-30 mai 2008; Marseille, France) ; Skuk D ; Paradis M ; Goulet M ; Tremblay J | 2008Nonhuman primates are the ideal animal models for preclinical transplantation studies. In addition, in the case of myoblast transplantation, the behavior of these cells is similar to humans, in contrast to other animal models. Unfortunately, the[...]Article
Congrès international de myologie 2008 (International Congress of Myology 2008; 26-30 mai 2008; Marseille, France) ; Skuk D ; Paradis M ; Goulet M ; Tremblay J | 2008The main constraint of the therapeutic strategy of intramuscularly injecting myogenic cells is that the implanted cells fuse only with the myofibers reached by the injection trajectories. An intravascular delivery of myogenic cells may be obviou[...]Article
Congrès international de myologie 2008 (International Congress of Myology 2008; 26-30 mai 2008; Marseille, France) ; Skuk D ; Paradis M ; Goulet M ; Tremblay J | 2008Duchenne muscular dystrophy (DMD) is characterized by a progressive destruction and ultimate disappearance of the skeletal muscle parenchyma, which is replaced by adipose and fibrous connective tissue. Previous reports about the involvement of n[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Benabdallah BF ; Bouchentouf M ; Tremblay J | 2005Communication n° 170. Background : Duchenne muscular dystrophy is caused by a dystrophin gene mutation. Transplantation of normal myoblasts results in long-term restoration of dystrophin. However, the success of this approach is compromised by t[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Lafreniere JF ; Mills PL ; Skuk D ; Tremblay J | 2005Communication n° 302 Introduction: One problem for the clinical application of myoblast transplantation for Duchenne Muscular Dystrophy (DMD) treatment is the poor migration of transplanted cells. Recently, we described a new approach that consi[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Skuk D ; Goulet M ; Roy B ; Tremblay J | 2005Communication n° 139 Introduction : Our Myoblast Allotransplantation Studies In Monkeys Showed That The Absence Of Immunosuppression Leads To Graft Rejection In A Few Days, While A Good Immunosuppression Allows Graft Survival Apparently As Long [...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Lafreniere JF ; Mills PL ; Tremblay J | 2005Communication n° 301 Introduction : Transplantation of myogenic cells is the only treatment that could reconstitute the satellite cell population of the muscle and introduce normal genes in pre-existing myofibers. One major problem that contribu[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; El Fahime E ; Benabdallah BF ; Tremblay J | 2005Communication n° 169 Therapies are currently investigating the use of the newly identified pluripotent muscle derived stem cells (MDSCs), as a possible cell-mediated therapy, in order to repopulate the dystrophic muscles. The existence of MDSCs,[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Quenneville SP ; Chapdelaine P ; Calos M ; Tremblay J | 2005Communication n° 425 Introduction : Duchenne Muscular Dystrophy (DMD) is the most severe muscular dystrophy. It is caused by the absence of dystrophin in muscle fibers. This absence leads to increased muscle damage. Myogenic cell transplantation[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Skuk D ; Goulet M ; Roy B ; Piette V ; Côte C ; Hogrel JY ; Bouchard JP ; Lachance JG ; Sylvain M ; Tremblay J | 2005Communication n°2 Introduction : Following a similar protocol as we used in monkeys, we observed that myoblast transplantation (MT), tested in only 1cm3 of muscle, systematically restored the expression of normal dystrophin in myofibers of DMD p[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Stéphan L ; Mills PL ; Pichavant C ; Tremblay J | 2005Communication n° 173 Duchenne muscular dystrophy (DMD) is a fatal neuromuscular recessive disease characterized by widespread muscle damage throughout the body. No cure is currently available for DMD. Our research group is pursuing a research pr[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Benabdallah BF ; Rousseau J ; Bouchentouf M ; Tremblay J | 2005Communication n° 172. Background : Duchenne muscular dystrophy is a severe myopathy caused by the absence of a functional dystrophin in muscles. Transplantation of normal myoblasts is a potential therapy that permits to restore the expression of[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Bouchentouf M ; Benabdallah BF ; Dumont M ; Tremblay J | 2005Communication n° 39. BACKGROUND : The quantification of the graft success is a key element to evaluate the efficiency of cellular therapies for several pathologies such as Duchenne muscular dystrophy. This study describes a novel approach to eva[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Lapointe E ; Ducharme ME ; Camirand G ; Kramer R ; Tremblay J ; Skuk D | 2005Communication n° 199 Introduction : Duchenne muscular dystrophy (DMD) is characterized by the absence of the dystrophin muscle protein (427 kDa). Delivery of normal dystrophin gene by myoblast transplantation permits the long term restoration of[...]